Basal insulin therapy in patients with type 2 diabetes mellitus: aspects of early initiation, advantages, constraints, and prospects
https://doi.org/10.14341/probl201157353-59
Abstract
Intensive control of glycemia starting from the onset of type 2 diabetes mellitus (DM2) is of primary importance for the long-term prognosis of the disease and the reduction of risk of cardiovascular complications. The strategy of early intensive therapy of DM2 thus far remains a matter of fierce dispute among diabetologists. The problem of choice of an optimal regime for the start of insulin therapy does not have an unambiguous solution either. Hypoglycemia is the main factor that traditionally hampers wide application of insulin therapy in patients with type 2 diabetes mellitus. The choice in favour of basal therapy with insulin analogs has the advantage of reaching the target parameters of carbohydrate metabolism at a significantly lower risk of hypoglycemia compared with other strategies of insulin therapy.
References
1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:14:977-986.
2. Nathan D.M., Cleary P.A., Backlund J.Y. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:25:2643-2653.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
4. Holman R.R., Paul S.K., Bethel M.A. et al. 10-year follow-up of intensive glucose control in type 2 diabetes mellitus. N Engl J Med 2008;359:1577-1589.
5. Patel A., MacMahon S., Chalmers J. et al. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
6. Gerstein H.C., Miller M.E., Byington R.P. et al. The Action to Control Cardiovascular Risk in Diabetes Study Group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
7. Duckworth W., Abraira C., Mortiz T. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
8. Turner R.C., Cull C.A., Frighi V. et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: prospective requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012.
9. Weng J., Li Y., Xu W. et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008;371:1753-1760.
10. Home P.D., Boulton A.J., Jimenez J. et al. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 2003;20:2:63-71.
11. Wright A., Burden A.C., Paisey R.B. et al. Efficacy of addition of insulin over 6 yers in patients with type 2 diabetes in the U. K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:2:330-336.
12. Monnier L., Lapinski H., Colette C. Contributions of Fasting and Postprandial Plasma Glucose increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients. Diabetes Care 2003;26:881-885.
13. Riddle M., Umpierrez G., Digenio A. et al. Challenging the «Monnier Concept»: High Basal (not Postprandial) Glucose Dominates Hyperglycemic Exposure over a Wide Range of A1C on Oral Therapy, and Contributes Significantly Even after Addition of Basal Insulin. Am Diabet Ass 2010;Abstract:626.
14. Nathan D.M., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association of the study of diabetes. Diabetes Care 2008;31:1-11.
15. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31:Suppl 1:S12-S54.
16. Guideline for management of postmeal glucose. International Diabetes Federation, 2007. [Available at: http://www.idf.org]
17. Алгоритмы специализированной помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой. М 2009.
18. Mäkimattila S., Nikkilä K., Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999;42:4:406-412.
19. Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33:6:1389-1394.
20. Sarwar N., Gao P. et al. Emerging Risk Factors Collaboration, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222.
21. Skyler J.S., Bergenstal R., Bonow R.O. et al. Intensive glycemic control nd the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Tials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-357.
22. Yki-Jarvinen H. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.
23. Riddle M. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
24. Rosenstock J., Dailey G., Massi-Benedetti M. et al. Reduced hypoglycemia risk with insulin glargine: a metaanalysis comparing insulin glargine with human NPH in type 2 diabetes. Diabetes Care 2005;28:950-955.
25. Mullins P., Sharplin P., Yki-Jarvinen H. et al. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin Glargine compared with Neutral Protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:8:1607-1619.
26. Gerstein H.C., Yale J.F., Harris S.B. et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:7:736-742.
27. Bretzel R.G., Nuber U., Landgraf W. et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084.
28. Залевская А.Г., Вербовая Н.И., Родионова Т.И. и др. Базальная инсулинотерапия у пациентов с сахарным диабетом типа 2 с неудовлетворительным контролем гликемии на пероральной сахарснижающей терапии: результаты прямого сравнительного исследования аналогов инсулина Лантус и Левемир. Сахарный диабет 2010;2:47:106-112.
29. Schreiber S.A., Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007;9:1:31-38.
30. The ORIGIN Trial Investigators Hamilton, Ontario, Canada Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:1:26-32.
31. The DECODE Study group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621.
Review
For citations:
Vikulova O.K. Basal insulin therapy in patients with type 2 diabetes mellitus: aspects of early initiation, advantages, constraints, and prospects. Problems of Endocrinology. 2011;57(3):53-59. (In Russ.) https://doi.org/10.14341/probl201157353-59
Views:
514
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
